MREO
Mereo BioPharma Group plc
+0.01 (+3.38%)0.28USD431K成交股數–市值–本益比(近四季)–股價營收比-100.0%營收年增(近四季)2026-11-09下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。外國發行人(20-F)通常只申報半年或年度,逐季會有缺。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 0.00-100% | 31K | 0.00 | 0.00 | 500K | 0.00-100% | 0.00 | 0.00-100% | 0.00 | 1.0M | 0.00 | 9.0M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 1.8M | 4.7M | 4.2M | 4.3M | 5.4M | 3.9M | 3.2M | 4.9M | 4.0M | 4.8M | 3.6M | 3.7M |
| 銷售管理費用 | 5.2M | 4.0M | 4.2M | 6.0M | 5.5M | 7.3M | 6.2M | 7.9M | 5.9M | 3.6M | 5.7M | 2.7M |
| 營業利益 | −7.0M-33% | −8.8M-22% | −8.4M-10% | −10.0M-22% | −10.5M+6% | −11.2M+57% | −9.4M+3% | −12.8M+1480% | −9.9M | −7.1M | −9.1M | −811K |
| 營業利益率 | – | -28,277.4% | – | – | -2,099.8% | – | – | – | – | -712.8% | – | -9.0% |
| 稅後淨利 | −7.0M-52% | −6.7M-48% | 76.4M-609% | −7.0M-43% | −14.6M+63% | −12.9M-126% | −15.0M+130% | −12.3M+600% | −9.0M | 49.8M | −6.5M | −1.8M |
| 淨利率 | – | -21,674.2% | – | – | -2,923.2% | – | – | – | – | 4,982.4% | – | -19.5% |
| 稀釋 EPS | -0.01-50% | -0.01-50% | 0.00-100% | -0.01-50% | -0.02+100% | -0.02+100% | -0.02+100% | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 |
| 稀釋股數 | 804M | 802M | 797M | 800M | 799M | 784M | 770M | 770M | 700M | 659M | 685M | 628M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 30.1M | 30.1M | 41.0M | 48.7M | 56.1M | 62.5M | 80.5M | 87.4M | 48.7M | 57.4M | – | – |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 34.7M | 40.6M | 45.9M | 53.6M | 62.6M | 68.3M | 88.7M | 96.1M | 55.9M | 66.5M | – | – |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 6.1M | 6.6M | 5.0M | 7.0M | 8.5M | 8.2M | 16.2M | 17.5M | 13.1M | 16.0M | – | – |
| 股東權益 | 28.7M | 34.1M | 40.9M | 46.6M | 54.2M | 60.1M | −72.5M | 78.7M | 42.8M | 50.5M | 54.7M | 49.7M |
| 負債比 | 17.5% | 16.2% | 10.9% | 13.1% | 13.5% | 12.1% | 18.3% | 18.2% | 23.4% | 24.0% | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −4.3M-48% | – | – | – | −8.3M | – | – | −8.0M | – | – | – |
| 資本支出 | – | 0.00 | – | – | – | 20K | – | – | 0.00 | – | – | – |
| 自由現金流 | – | −4.3M-48% | – | – | – | −8.3M | – | – | −8.0M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -13,909.7% | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 500K | – | 41.9M | 8,375.6% | -0.05 | −31.0M |
| FY2024 | 0.00 | -100.0% | 43.3M | –% | -0.06 | −32.8M |
| FY2023 | 10.0M | – | 29.5M | 294.7% | -0.04 | −21.1M |
| FY2022 | 0.00 | – | −42.2M | –% | -0.07 | −48.8M |